Axsome Therapeutics AXSM Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's financing cash flow?
- Axsome Therapeutics (AXSM) reported financing cash flow of $2.99M in Q1 2026.
- How has Axsome Therapeutics's financing cash flow changed year-over-year?
- Axsome Therapeutics's financing cash flow decreased by 89.8% year-over-year, from $29.27M to $2.99M.
- What is the long-term trend for Axsome Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Axsome Therapeutics's financing cash flow has grown at a 73.8% compound annual growth rate (CAGR), from $11.13M to $101.47M.
- What does financing cash flow mean?
- The net change in cash resulting from borrowing, repaying debt, and issuing or buying back stock.
- How do you interpret financing cash flow?
- Positive net cash indicates the company is raising capital; negative net cash indicates the company is paying down debt or returning capital to shareholders.
- How does financing cash flow compare across companies?
- Highly variable; clinical-stage companies typically show positive net financing cash flow to fund R&D, while mature companies often show negative.